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Abstract
Background: Pleiotrophin is known to promote the survival and differentiation of dopaminergic neurons in vitro
and is up-regulated in the substantia nigra of Parkinson’s disease patients. To establish whether pleiotrophin has a
trophic effect on nigrostriatal dopaminergic neurons in vivo, we injected a recombinant adenovirus expressing
pleiotrophin in the substantia nigra of 6-hydroxydopamine lesioned rats.
Results: The viral vector induced pleiotrophin over-expression by astrocytes in the substantia nigra pars compacta,
without modifying endogenous neuronal expression. The percentage of tyrosine hydroxylase-immunoreactive cells
as well as the area of their projections in the lesioned striatum was higher in pleiotrophin-treated animals than in
controls.
Conclusions: These results indicate that pleiotrophin over-expression partially rescues tyrosine hydroxylase-
immunoreactive cell bodies and terminals of dopaminergic neurons undergoing 6-hydroxydopamine-induced
degeneration.
Background
Parkinson’s disease is a neurodegenerative disorder char-
acterized by a gradual loss of dopaminergic neurons in the
substantia nigra, leading to a progressive reduction of
dopamine levels in the striatum. Parkinson’s disease
mainly affects motor function causing bradykinesia, tre-
mor, rigidity, and postural imbalance, which appear after a
significant number of dopaminergic neurons have died [1].
The underlying pathogenesis of Parkinson’s disease is
poorly understood and the current pharmacological and
surgical therapies only offer symptomatic relief [2]. Several
recent studies have investigated different neuroprotective
treatments aimed at stopping or slowing down the degen-
erative process by restoring dopaminergic function or
protecting the dopaminergic neurons undergoing degen-
eration. Some of these approaches involve embryonic stem
cell transplantation and delivery of neurotrophic and neu-
ronal growth factors such as glial cell line-derived neuro-
trophic factor (GDNF) [3,4]. Since most of the treatments
that have reached a clinical stage have not been successful,
further research in this field is warranted.
Pleiotrophin (PTN), a developmentally-regulated
secreted heparin-binding protein, was initially recognized
as a neurite outgrowth-promoting factor present in the
rat brain in perinatal stages [5]. During embryonic and
early postnatal development, PTN is expressed along
axon pathways and is believed to promote neuronal dif-
ferentiation and the establishment of synaptic connec-
tions [6]. Recent studies show that PTN mRNA increases
in the adult striatum after nigrostriatal lesions [7] and
chronic levodopa therapy [8]. Furthermore, PTN pro-
motes survival [7,9] and differentiation [10] of dopamine
neurons in primary mesencephalic cultures, and increases
the differentiation of dopamine neurons from embryonic
stem cells [11]. Here we have studied the distribution of
PTN in the substantia nigra and the effect of PTN over-
expression as a potential trophic factor influencing the
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Results
Endogenous pleiotrophin expression by dopaminergic
neurons but not astrocytes in the adult substantia nigra
Prior studies describing the distribution of PTN in the
brain provide limited information on PTN expression in
the adult substantia nigra. As our aim was to induce PTN
expression in the substantia nigra by using a viral vector,
it was important to obtain information on the characteris-
tics of endogenous expression, to differentiate it from
over-expression. Pleiotrophin immunoreactivity is scarce
in the adult ventral mesencephalon. Around 50% of the
PTN-immunoreactive cells located in the substantia nigra
pars compacta are tyrosine hydroxylase (TH)-immunor-
eactive neurons, and overall, 18% of the TH-immunoreac-
tive neurons express PTN (Figure 1A and 1B). PTN
expression in the substantia nigra seemed to be restricted
to neurons, while astrocytes are not PTN-immunoreactive
in normal rats or in rats with 6-hydroxydopamine (6-
OHDA) induced lesion (Figure 1C). Consistent with the
view that at least some dopaminergic neurons express
PTN, its immunoreactivity decreased in the substantia
nigra after 6-OHDA injection in the striatum (Figure 1D).
As our ultimate goal was to establish whether local
PTN over-expression has trophic effects on dopaminer-
gic neurons, it was important to know if dopaminergic
neurons express PTN receptors. Previous work estab-
lished that mesencephalic dopaminergic neurons express
the receptor protein tyrosine phosphatase type zeta beta
(RPTP-ζ/b) [12], one of the main receptors for PTN.
We found that another important PTN receptor, the
heparin sulfate proteoglycan N-syndecan [13] is also
expressed by neurons in the substantia nigra pars com-
pacta (Figure 2). Triple immunolabeling for TH, PTN
and N-syndecan shows that N-syndecan may be
expressed together with PTN and TH in the same neu-
ron, in TH-immunoreactive neurons that do not express
PTN, and in non-dopaminergic neurons (Figure 2).
Overall, 18 ± 3% TH-immunoreactive neurons express
N-syndecan, and 75 ± 7% of the N-syndecan positive
neurons are immunoreactive to TH (mean ± SEM, n =
3). Moreover, the populations of dopaminergic neurons
that express N-syndecan or PTN do not overlap com-
pletely, with only 3% of the TH positive neurons expres-
sing both markers. In summary, PTN and its receptors
are expressed in the substantia nigra and may co-exist
in dopaminergic neurons.
Adenoviral vector induced PTN over-expression in
astrocytes
Over-expression of PTN, induced by the injection of the
adenoviral vector (AdPTN) in the rostral pole of the
substantia nigra pars compacta, differed markedly from
the observed endogenous pattern. AdPTN injection
induced PTN over-expression throughout the rostrocau-
dal extension of the substantia nigra pars compacta,a t
7 and 14 days after injection (Figure 3A and 3B). The
over-expressing cells were immunoreactive to the glial
fibrillary acidic protein (GFAP) (Figure 3C). Moreover,
over-expression was higher at 7 than at 14 days post-
injection (Figure 3B), as shown previously with other
adenoviral vectors [14,15]. Seven days after AdPTN
injection, 83 ± 4% of the PTN-immunoreactive glial-like
cells were also GFAP-immunoreactive (mean ± SEM,
n = 3). Importantly, despite the induction of reactive
astrocytosis at the injection site by both AdPTN and the
control adenovirus encoding b-galactosidase (Adbgal),
astrocyte immunolabeling was only present in AdPTN
injected animals (Figure 3B). Thus, over-expression of
PTN mainly occurred in astrocytes, not as a non-specific
consequence of viral infection, but only in animals trea-
ted with the vector carrying the PTN genetic code.
Inflammatory response and neuronal PTN expression
after infection
As in previous studies, adenoviral injections induced an
inflammatory process and local non-specific neuronal
damage [14,15]. Here the inflammatory infiltrate con-
sisted mainly of macrophages, it extended caudally into
the substantia nigra pars compacta,a n dw a sh i g h e r7
than 14 days after injection (Figure 4A), much like as in
the study by De Lella Ezcurra et al. (2010). Most of the
cells in the infiltrate were immunoreactive to ED1, a
marker of macrophages and microglia with phagocytic
activity [16] while some were immunoreactive to Mac1,
a marker of macrophages and resting and activated
microglia [17,18] (Figure 4B). Even though in very rare
instances (< 2%) ED1+ or Mac1+ cells in the infiltrate
could be immunoreactive for PTN (Figure 4B), this
most certainly reflects phagocytosis of debris rather than
adenoviral infection of cells in the infiltrate.
To characterize the effect of adenoviral infections on
endogenous neuronal expression of PTN we counted PTN
and TH-immunoreactive neurons in double labeled sec-
tions in normal rats 7 days after injections of Adbgal or
AdPTN (Table 1; see also Figure 3B). Rats injected with
the viruses showed normal percentages of PTN-TH posi-
tive neurons, suggesting that adenoviral infection does not
modify the expression of PTN in dopaminergic neurons.
PTN over-expression partially rescues dopaminergic
markers in the substantia nigra and striatum
To establish whether PTN over-expression has neuro-
protective effects on dopaminergic neurons, rats were
injected with Adbgal or AdPTN in the substantia nigra
seven days after being injected with 6-OHDA or vehicle
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Page 2 of 12in the striatum (Figure 5). In rats receiving 6-OHDA
injections in the dorsal striatum neuronal degeneration
in the substantia nigra pars compacta develops rapidly
between the first and the second week, slowing down
after that, but still remaining significant for several
weeks [19]. Thus, in our experiment, dopaminergic neu-
ronal death would have started well before PTN over-
expression reaches a maximum, at some point during
the two weeks following adenoviral infection. More
importantly, the degenerative process would have been
in progress during the two weeks that followed AdPTN
injection. Therefore, the experiment simulates a timing
that resembles, to some extent, that of a hypothetical
neuroprotective therapy in the clinical setting. Rats were
sacrificed 14 days after adenoviral injection (21 days
after 6-OHDA injection) to study the remaining nigros-
triatal system by counting TH-immunoreactive cells in
the substantia nigra (Figure 6) and measuring the area
occupied by TH-immunoreactive terminals in striatal
sections (Figure 7).
Analysis of cell counts by means of a two-way
ANOVA revealed significant effects of PTN over-expres-
sion (p = 0.0297) and lesion (p = 0.0018), and no inter-
action between these factors (p = 0.2389). Although this
Figure 1 Pleiotrophin is expressed by dopaminergic neurons but not by astrocytes in the adult substantia nigra pars compacta.( A) Bar
graph showing the distribution of cells immunoreactive for PTN and TH in the substantia nigra pars compacta of adult normal rats: 18 ± 4% of
TH-immunoreactive neurons expressed PTN (TH-PTN/total TH) and 48 ± 5% of PTN-immunoreactive cells were also TH-immunoreactive neurons
(TH-PTN/total PTN). Mean ± SEM, n = 3. (B) Photomicrograph shows the double fluorescence of PTN (red) and TH (green) in adult normal rats.
The white arrows indicate double-labeled cells (yellow). (C) The double fluorescence of PTN (red) and GFAP (green) indicates that astrocytes are
not PTN-immunoreactive in normal rats. (D) Expression of PTN (red) and TH (green) in normal and 6-OHDA lesioned animals. The photographs
were taken from the area indicated in the Paxinos and Watson atlas plate corresponding to bregma -4.80 mm (inset). Scale bars: B and C, 50
μm; D, 200 μm.
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the number of TH-immunoreactive neurons both in
sham and 6-OHDA-lesioned animals, the increase was
only 4% in controls but 14% in the lesioned rats (from
50 to 64% remaining neurons) (Figure 6), suggesting
that PTN over-expression had its main effect in the par-
kinsonian condition. Moreover, PTN over-expression
selectively increased the striatal area innervated by TH-
immunoreactive fibers in 6-OHDA-lesioned animals (p
= 0.0044, lesion × treatment interaction in a two way
ANOVA, Figure 7). Thus, the data show that PTN over-
expression partially rescues TH immunoreactivity in cell
bodies and terminals of dopaminergic neurons under-
going 6-OHDA-induced degeneration.
Discussion
Increasing evidence links PTN to dopamine neuron sur-
vival and differentiation. Early evidence showing that
PTN promotes survival and neurite extension in cul-
tured dopaminergic neurons [7,10] has been confirmed
recently [9] and extended to embryonic dopaminergic
cells transplanted into the adult striatum [20]. Together
Figure 2 N-syndecan, a receptor for pleiotrophin, is expressed by nigral dopaminergic neurons. Triple immunolabeling in the substantia
nigra pars compacta for TH (A, blue), N-syndecan (B, green) and PTN (C, red) showing co-localization of the three markers in some neurons
(solid arrow-heads). The open arrow-head indicates a cell that only contains N-syndecan, the open arrow indicates a cell that contains PTN and
TH, and the solid arrows indicate cells immunoreactive for TH that do not contain PTN or N-syndecan. Scale bar: 50 μm.
Taravini et al. Molecular Neurodegeneration 2011, 6:40
http://www.molecularneurodegeneration.com/content/6/1/40
Page 4 of 12with the fact that PTN expression peaks perinatally and
then decreases with age [21,22], these findings prompted
studies exploring the role of PTN in the development of
dopaminergic neurons. Thus, PTN induces the differen-
tiation of mouse embryonic stem cells to dopaminergic
neurons [11] and has recently been identified as one of
the main stromal-derived factors inducing dopaminergic
neurons from human embryonic stem cells [23]. Despite
this strong evidence of PTN trophic effects on embryo-
nic dopaminergic neurons, in vivo evidence of a trophic
role of PTN in the adult nigrostriatal system was
lacking.
In agreement with previous postmortem studies in the
adult human brain [9], we found that PTN is expressed
by neurons but not glial cells in the normal adult rat
substantia nigra. This is consistent with findings show-
ing widespread neuronal and glial expression of PTN
perinatally and confinement of expression to neurons in
the adult brain [21,22]. We also found that N-syndecan,
one important receptor for PTN, is expressed by neu-
rons in the ventral mesencephalon and can coexist with
PTN in some dopaminergic neurons. A recent study
[12] showed that one of the main receptors for PTN,
RPTP-ζ/b, is also expressed in adult dopaminergic neu-
rons, and maintains its expression in rats with partial
nigrostriatal lesion induced by 6-OHDA. Importantly,
PTN trophic effects on cultured dopaminergic neurons
appear not to be mediated by products released by glial
cells, but seem to result from a direct action of PTN on
dopaminergic neurons [9]. Finally, antibodies against
PTN reduce the viability of cultured PC12 cells, a proto-
typical catecholaminergic cell line, suggesting that PC12
cells support themselves through PTN release [24].
More studies are needed to determine if adult dopami-
nergic neurons depend on trophic support through an
autocrine/paracrine pathway involving PTN in vivo.
However, additional mechanisms can have contributed
to the trophic effects seen in vivo in our experiments,
Figure 3 Astrocytes over-express pleiotrophin after AdPTN infection.( A) Coronal plates from the Paxinos and Watson atlas illustrating the
site of injection of the adenoviruses (left) and the region of the substantia nigra from which the microphotographs have been taken (right). (B)
Immunohistochemical detection of PTN on coronal sections at mesencephalic level after AdPTN or Adbgal injection, 7 and 14 days post-
injection, in adult normal rats. The strong PTN-immunoreactivity in glial-like cells is only seen in animals treated with AdPTN. The squares in the
low magnification images indicate the area shown in the high magnification ones (bottom panel of images). Scale bars: 500 μm (low
magnification images) and 100 μm (high magnification images). (C) Double immunohistochemistry showing the co-localization of GFAP and PTN
in astrocytes in a control rat 7 days after AdPTN injection. Scale bar: 50 μm.
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instance, PTN could have changed the properties of the
extracellular matrix, where it also has receptors [25], or
could have promoted the release of additional molecules
from astrocytes, thus having indirect effects on dopami-
nergic neurons [10].
In patients, Parkinson’s disease is diagnosed months to
years after the degeneration of dopaminergic neurons has
begun, precluding the use of preventive therapies [1]. An
ideal model mimicking the degenerative process, as it
takes place in patients, is lacking. However, rats treated
with 6-OHDA in the striatum show a protracted degen-
eration of dopaminergic neurons that spans several
weeks, thus allowing the trial of neuroprotective thera-
pies well after the degenerative process has started [19].
We undertook, what may seem, a challenging path to
decide on the potential of PTN as a neuroprotective
therapy in Parkinson’s disease. First, we developed an
adenoviral vector to induce PTN expression in the brain
which provided a time window of maximal expression
during the two weeks that follow the infection. Second,
we used a well characterized experimental model of Par-
kinson’s disease [19], showing peak rates of cell death
during the first two weeks after intrastriatal 6-OHDA
injection, and decided on applying PTN therapy after
the first week, during a protracted and less intense
phase of neuronal degeneration. Thus, although the
trophic effect of PTN over-expression reported here can
be perceived as modest compared with that of GDNF
[26], it needs to be weighed against the fact that only a
fraction of the dopaminergic neurons that had been
damaged by the 6-OHDA injection could have been
Figure 4 Inflammatory response after adenoviral infection.( A) Inflammatory infiltrate induced by the adenoviruses as seen in Nissl stained
sections in normal rats. The coronal sections correspond to the same Paxinos and Watson stereotaxic atlas plate shown in Figure 3A (right). The
infiltrate has a similar extension in Adbgal and AdPTN injected rats and was higher at 7 than 14 days after injection. Scale bars: 500 μm (low
magnification images) and 100 μm (high magnification images). (B) Microphotographs showing activated macrophages labeled with antibodies
against ED1 (left) or Mac1 (right), in double labeling with PTN (red). Scale bars: 50 μm.
Table 1 Effect of adenovirus injection on neuronal PTN
expression
% of Double labeled cells (mean ± SEM)
Group TH-PTN/total TH TH-PTN/total PTN
Control rats (no treatment) 15 ± 1 43 ± 4
Rats injected with Adbgal 14 ± 1 47 ± 3
Rats injected with AdPTN 18 ± 5 46 ± 5
n = 3 rats per group. No significant differences were found (one-way ANOVA).
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observed could be close to the maximum achievable
recovery under the conditions of our study. Inducing
PTN over-expression before injecting 6-OHDA could
have increased the chances of seeing a larger effect by
allowing therapy to target a wider population of injured
dopaminergic neurons. However, the conditions we used
more closely resemble those of the actual clinical
condition.
Critical to the success of our approach was the
choice of the vector injection site. For unclear reasons,
viral injections at the rostromedial pole of the substan-
tia nigra pars compacta produced an infection that
spread throughout the rostrocaudal extent of the sub-
stantia nigra pars compacta, with negligible involve-
ment of other structures. Vector injections dorsal or
caudal to the selected site, or within the substantia
nigra itself, did not reproduce this infection pattern
(not shown). Also, the fact that astrocytes seem to be
preferentially infected would have allowed a local
source of PTN without adding additional stress to the
i n j u r e dd o p a m i n e r g i cn e u r o n s .Ar e c e n ts t u d yb yP i l t o -
nen et al (2009) reported that a single injection of
PTN in the striatum followed by an injection of 6-
OHDA in the striatum resulted in less behavioral
impairment than intrastriatal 6-OHDA injection alone
[27]. However, the number of TH-immunoreactive
neurons in the substantia nigra was similar in both
experimental groups in the study carried out by Pilto-
nen, leaving open the possibility that functional
changes in the striatum could account for the beha-
vioral results (see also [12]). In addition to the site of
administration, timing and duration of PTN treatment,
several other methodological differences can account
for the discrepancy between our findings and those of
Piltonen. However, the data agree in that PTN could
be of potential benefit in Parkinson’s disease.
The mechanism by which PTN could act on injured
dopaminergic neurons remains unclear. As PTN over-
expression had no effect in control rats, our findings
support the idea that PTN provided trophic support to
dopaminergic cells that remained viable but were in a
dysfunctional and/or dystrophic state. Pleiotrophin
could also stimulate axonal dopaminergic sprouting
towards denervated regions in the striatum. It has been
reported that dopaminergic cells can lose their
Figure 5 Pleiotrophin over-expression was induced after the lesion to mimic more closely a possible use in patients.S c h e m a t i c
illustration of the experimental design. Rats were injected with Adbgal or AdPTN in the substantia nigra seven days after being injected with 6-
OHDA or vehicle in the striatum. The animals were sacrificed 14 days after adenoviral injections (21 days after 6-OHDA injection). Histology and
immunohistochemistry were performed on free-floating coronal serial tissue sections of the entire striatum and substantia nigra. Beta-
galactosidase activity was detected using X-gal as substrate (A). Pleiotrophin (B) and TH (C and D) were revealed with DAB as chromogen. The
microphotographs were taken from sections of 6-OHDA lesioned rats treated with Adbgal (A and D) or AdPTN (B and C).
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exclude that PTN has simply allowed the maintenance
of the TH phenotype in injured dopaminergic neurons.
Two methods have been proposed to distinguish loss of
phenotype from cell death in the dopaminergic system:
counting Nissl stained neurons in the substantia nigra
pars compacta and counting nigral neurons retrogradely
labeled by anatomical tracers injected into the striatum.
Concerning Nissl staining, in our experience, a non-neg-
ligible number of neurons located within the substantia
nigra pars compacta region can be non dopaminergic
(see for example the TH negative neurons in Figure 2).
Moreover, the method is very sensitive to the drawing
of pars compacta limits, which are not easy to deter-
mine when part of the dopaminergic system has degen-
erated, allowing changes in the microanatomy of the
ventral mesencephalon. Finally, there are many dopami-
nergic neurons that normally reside in the pars reticu-
lata and escape this analysis. Concerning retrograde
labeling, it seems likely that dopaminergic neurons can
lose their striatal terminals without dying [28]. Despite
these caveats, TH immunoreactivity has been widely
used as a marker of both dopaminergic cell viability and
dopaminergic terminals integrity. In our study, there is
significant consistency in the finding of both increased
TH immunoreactivity in the substantia nigra and in
striatal terminal fields in animals over-expressing PTN.
Several trophic factors have been shown to promote
the recovery or protect the dopaminergic system in ani-
mal models of Parkinson’s disease, among which GDNF
is thought to be the most efficacious [29-31]. However,
clinical trials in Parkinson’s disease patients delivering
GDNF failed to produce significant clinical benefits
probably because of either inadequate site of administra-
tion or the appearance of side effects [32-34]. Although
the mechanisms of PTN induced effects remain obscure,
maintenance or recovery of dopaminergic markers
should be seen as a positive indicator of its potential
benefit in Parkinson’s disease. Our data bring hope on
the possibility that a PTN-based therapy could target
Figure 6 Pleiotrophin over-expression rescues TH-immunoreactive cell bodies in the substantia nigra pars compacta (SNpc).( A) Values
(mean ± SEM) are the percentage of TH-immunoreactive (TH-ir) neurons remaining in the substantia nigra injected with AdPTN or Adbgal
compared to the contralateral substantia nigra (100%). Sham/Adbgal: 68 ± 5% (n = 9), Sham/AdPTN: 72 ± 3% (n = 9), 6-OHDA/Adbgal: 50 ± 4%
(n = 10), 6-OHDA/AdPTN: 64 ± 3% (n = 11). (B) Photomicrographs show TH immunohistochemistry in a coronal section (-5.3 mm from bregma)
from a representative animal of each experimental group, at low (left) and high (right) magnification. Note the higher number of remaining cell
bodies in the 6-OHDA rat treated with AdPTN (high magnification image). Consistent with the view that PTN over-expression rescued TH-
immunoreactive neurons, post hoc analysis revealed a significant effect of PTN over-expression in 6-OHDA-lesioned animals (*p< 0.05, Student
Neuman Keuls). Although it is not indicated in the figure for simplicity, the post hoc comparison between Sham/Adbgal and 6-OHDA/Adbgal is
also significant at p < 0.05 level. Scale bars: 500 μm (low magnification images) and 50 μm (high magnification images).
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condition.
Conclusions
We found that: i. PTN and one of its receptors, N-syn-
decan, are expressed to a moderate extent in the adult
substantia nigra and can co-exist in dopaminergic neu-
rons; ii. in contrast to nigral endogenous expression,
which is exclusively neuronal in the adult, adenoviral
vector-induced PTN over-expression occurs in astrocytes;
iii. PTN over-expression has protective effects on dopami-
nergic cell bodies in the substantia nigra and striatal term-
inals as evaluated through TH immunohistochemistry in
rats with partial nigrostriatal lesion. Although the
mechanism by which PTN could act on dopaminergic
neurons undergoing degeneration remains unclear our
findings suggest that PTN could provide trophic sup-
port to dopaminergic cells that remained viable but
were in a dysfunctional and/or dystrophic state.
Further experiments using different delivery techni-
ques, time courses, or animal models should be per-
formed to validate our findings and to provide a better
explanation of its mechanism of action. Pleiotrophin
could then become a potential therapeutic tool, for the
design of strategies of neuroprotection and neurores-
toration in Parkinson’s disease.
Figure 7 Pleiotrophin over-expression rescues TH-immunoreactive terminals in the striatum.( A) Tyrosine hydroxylase-immunoreactive
(TH-ir) area in the 6-OHDA or vehicle injected striatum of Adbgal and AdPTN treated animals (percent of contralateral side). Sham/Adbgal: 90 ±
1%, Sham/AdPTN: 90 ± 1%, 6-OHDA/Adbgal: 53 ± 3%, 6-OHDA/AdPTN: 63 ± 2%. Student Neuman Keuls post hoc test, after significant interaction
in a two-way ANOVA and Logit transformation of the variable [38], *p< 0.05. Mean ± SEM. (B) Outlines on photomicrographs illustrate the area
used for optical density measurements on a representative coronal section of the striatum (+0.20 mm from bregma). Scale bar: 500 μm.
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Vectors
We used a recombinant adenoviral vector to over-
express PTN, AdPTN, in the rat substantia nigra.T h e
vector was generated by homologous recombination in
human embryonic kidney 293 cells (HEK293) as pre-
viously described [16]. For construction of AdPTN,
human PTN cDNA was cloned into a shuttle vector
with a human cytomegalovirus promoter and cotrans-
fected into HEK293 cells with a plasmid containing E1-
to E3-deleted type 5 adenoviral genome. Human PTN
differs from rat PTN in only one aminoacid [35]. The
correct recombination was verified by restriction diges-
tions of the purified viral DNA obtained by HIRT. The
adenoviral vector was purified by plaque-formation
under agar. The control adenovirus encoding b-galacto-
sidase, Adbgal, was kindly provided by Dr J. Mallet
(Hôpital de la Salpêtrière, Paris, France). Recombinant
adenovirus were propagated in HEK293 cells and puri-
fied by double cesium chloride gradient centrifugation
and sephadex chromatography. The final titer was deter-
mined testing the ability to form plaques on HEK293
cell monolayers and by optical absorbance. The final
titers of the viral stocks were Adbgal = 1.25 × 10
9 pfu/
μl and AdPTN = 1.47 × 10
9 pfu/ μl (total particles/
infective particles ratio: Adbgal = 6.0 and AdPTN =
5.6). Quality controls, performed as described before
[16], determined that stocks had less than 0.06 EU/ml
of endotoxin as tested by the E-toxate assay (Sigma,
USA) and were free of autoreplicative particles as
assessed by PCR against the adenoviral E1 region.
Animals
The study was performed on adult female Wistar rats
weighing 220-250 g at the beginning of the experiments.
Animals were caged in groups of five, in a temperature-
controlled room (20°C ± 2°C), with a 12:12 h light/dark
cycle, and ad libitum access to food pellets and tap
water. All surgical procedures and techniques used for
the administration of recombinant adenoviral vectors
were performed in accordance with European Council
Directive 86/609/EEC guidelines for the care of labora-
tory animals and the regulations for the Care and Use
of Laboratory Animals under S2 biosafety levels of the
National Institutes of Health, USA. Animal experiments
were approved by our local Ethics Committee. The ani-
mals were anesthetized with ketamine/xylazine (40/2
mg/kg, i.p.) before surgical procedures.
Intrastriatal 6-OHDA lesion and adenoviral injections
Under deep anesthesia, rats received a stereotaxic injec-
tion of 6-OHDA (Sigma, USA. 20 μg/4 μl, 0.55 μl/min)
in the left striatum, so as to produce a protracted partial
degeneration of the nigrostriatal pathway, or vehicle
(0.02% ascorbic acid in saline) [19]. Stereotaxic coordi-
nates from bregma (mm): 1.0 anterior, 3.0 lateral and
4.5 ventral [36]. In our hands 74 ± 1% TH-immunoreac-
tive neurons remain in the substantia nigra pars com-
pacta and 55 ± 2% of the striatal area is still
immunoreactive to TH, twenty-one days after 6-OHDA
injection (mean ± SEM, n = 10). Seven days after sur-
gery, sham and 6-OHDA operated animals were ran-
domly assigned to receive Adbgal or AdPTN in the
rostral pole of the left substantia nigra pars compacta
(4.5 mm posterior and 1.5 mm lateral from bregma, 7.8
mm ventral from dura) [36]. Both AdPTN and Adbgal
were diluted in sterile 10 mM Tris-HCl, 1 mM MgCl2
(pH 7.8) and administered at a dose of 1 × 10
7 pfu/ μl/
rat based on preliminary experiments. The animals were
sacrificed at 21 days post 6-OHDA injection. Additional
experiments were performed in naïve and 6-OHDA-
lesioned rats to establish the normal pattern of expres-
sion in the mesencephalon and the time course of PTN
over-expression.
Histology and immunohistochemistry
At the end of the experiments the animals were deeply
anesthetized and perfused transcardially with 100 ml of
heparinized saline followed by 200 ml of cold 4% paraf-
ormaldehyde in 0.1 M phosphate buffer. Brains were
dissected out, post-fixed for 30 min in the same fixative
solution and cryoprotected in 30% sucrose in 0.1 M
phosphate-buffered saline (PBS) for 48 hours. The stria-
tum and substantia nigra were serially sectioned in a
freezing microtome and the free-floating coronal 25-
μm-thick tissue sections were stored in PBS containing
0.1% sodium azide at 4°C. These sections were used to
perform either cresyl violet staining or immunohisto-
chemistry. Beta-galactosidase activity was detected using
X-gal (5-bromo-4-chloro-3-indoyl-b-D-galactopyrano-
side) as substrate as published before [16].
Pleiotrophin expression was determined on free-float-
ing coronal serial sections encompassing the entire sub-
stantia nigra. During all staining procedures 0.1 M PBS,
0.3% Triton X-100 (PBS-T) was used for diluting all
immunoreagents and for washing between all antibodies
incubations. Sections were incubated in 0.5% H2O2 fol-
lowed by 10% normal goat serum (NGS) in PBS-T and
exposed to a rabbit anti-PTN antiserum (1:100, Santa
Cruz Biotechnology, USA) for 48 hours at 4°C. Pre-
adsorption of the antiserum with recombinant PTN pro-
tein almost completely abolished the labeling of bands
in western blots and abolishes cell staining in tissue sec-
tions [37]. After washing, the sections were incubated
with biotin-labeled anti-rabbit IgG antiserum (1:250,
Vector Laboratories, USA). The presence of the primary
antibody was visualized by means of an avidin-biotin
peroxidase complex (1:125, Vectastain, ELITE ABC kit,
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minobenzidine tetrahydrochloride (DAB) (Sigma, USA)
and 0.015% H2O2. TH immunoreactivity was deter-
mined in the striatum and in the sections of the mesen-
cephalon adjacent to those stained for PTN, following
the basic immunohistochemistry protocol described
above with slight variations. Sections were incubated in
0.3% H2O2 f o l l o w e db y2 %N G Sa n dt h e ne x p o s e dt oa
rabbit anti-TH antiserum (1:1000, Pel Freeze Biologicals,
USA) overnight at 4°C. After rinsing, sections were incu-
bated with a biotinylated anti-rabbit IgG (1:250, Vector
Laboratories, USA) and the antibody-antigen complex
was visualized as described above.
Double-fluorescent labeling was done sequentially.
After incubation in 2% NGS, sections were further incu-
bated with the anti-PTN antiserum for 48 hours, and
after rinsing, exposed for 24 hours at 4°C to the second
primary antibody: (i) mouse anti-TH (1:500, DiaSorin,
Italy); (ii) mouse anti-GFAP (1:4000, Sigma) for astro-
cytes; (iii) mouse anti-ED1 (1:200, Serotec, USA) for
macrophages and microglial cells with phagocytic activ-
ity; or (iv) rat anti-Mac1 (kindly provided by Mirta Gior-
dano, National Academy of Medicine, Argentina) for
macrophages, resting and activated microglia. Sections
were exposed to the biotin-labeled anti-rabbit IgG anti-
serum (Vector Laboratories), and after washing, to
streptavidin-Cy3 (Sigma) to unveil the anti-PTN antibo-
dies, and then, to anti-mouse IgG or anti-rat IgG
Alexa
® 488 labeled antibodies (1:200, Molecular Probes,
USA). PTN, TH and the receptor for PTN, N-syndecan
were immunolabeled in the same tissue sections. PTN
was determined as described before and the anti-TH
antibodies were revealed with anti-mouse IgG-Cy5
(1:200, Jackson ImmunoResearch, USA). N-syndecan
immunoreactivity was detect by incubation with a goat
anti-N-syndecan (1:200, Santa Cruz Biotechnology) for
24 hours at 4°C and then sections were exposed to anti-
goat Alexa
® 488 labeled antibodies (1:200, Molecular
Probes).
Images of DAB immunolabeled sections were captured
with an Eclipse 50i Nikon microscope equipped with a
Nikon DS-5MCL1 cooled camera. Fluorescent images
were acquired with an Olympus FV300 confocal micro-
scope connected to a video camera on line with an
Olympus FluoView digital image analyzer.
Quantification
In normal animals, the proportion of fluorescent labeled
cells was estimated from direct counts on eight sections
encompassing the rostrocaudal extension of the substan-
tia nigra pars compacta (400x magnification). In sham
and lesioned animals injected with AdPTN or Adbgal
TH immunoreactive cells were blindly counted using
a 40x objective in the ipsilateral and contralateral
substantia nigra pars compacta every eighth 25- μm-
thick coronal section in which transgene expression was
evident (a total of four sections covering the substantia
nigra between 4.7 and 5.3 mm posterior to bregma) [36].
The percentage of TH-immunoreactive area was deter-
mined on the lesioned striatum on every twelfth 25- μm-
thick coronal section (a total of six sections covering the
striatum between 1.6 and -0.4 mm related to bregma)
[36]. Optical density measurements were performed
using the National Institutes of Health (USA) ImageJ
software.
Statistical analysis
Results are presented as means ± SEM. To compare the
effects of lesion and adenovirus treatments on the num-
ber of TH-immunoreactive cells in the substantia nigra
pars compacta and the TH-immunoreactive area in the
striatum, a two-way ANOVA followed by Student Neu-
man Keuls post hoc test was used. Before performing
the parametric statistical analysis the variables were
tested for normality and variance homogeneity. The
data has passed tests for normality, but striatal areas
showed unequal variances and were transformed to
achieve this statistical requirement according to Festing
(2001). A value of p < 0.05 was considered statistically
significant.
Acknowledgements
This study was supported by grants from the Argentine Agency for the
Promotion of Science (PICT-2002 11063, PICT-2005 33465 and PICT-2005
31988), René Barón Foundation, University of Buenos Aires (UBACyT-M037,
M025 and M050) and the National Parkinson Foundation (Miami, Florida.).
IRET and MC are research fellows of the Argentine National Research Council
(CONICET). EGC, MGM and FJP are members of the research career of
CONICET. We would like to thank Juan Ferrario, Celia Larramendy, Mariano
Saborido and Silvina Diaz for helpful discussion and continuous support.
Author details
1Laboratorio de Parkinson Experimental, Instituto de Investigaciones
Farmacológicas (ININFA-CONICET-UBA). Ciudad Autónoma de Buenos Aires,
Argentina.
2Laboratorio de Terapias regenerativas y protectoras de sistema
nervioso, Fundación Instituto Leloir, CONICET. Ciudad Autónoma de Buenos
Aires, Argentina.
3Laboratorio de Terapia Molecular y Celular, Fundación
Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos Aires,
CONICET. Ciudad Autónoma de Buenos Aires, Argentina.
4CNRS UMR 7149,
Laboratoire CRRET, Croissance Cellulaire, Réparation et Régénération
Tissulaire, Créteil, France.
5Laboratorio de Fisiología de Circuitos Neuronales,
Departamento de Fisiología y Biofísica, Facultad de Medicina, Universidad de
Buenos Aires. Ciudad Autónoma de Buenos Aires, Argentina.
Authors’ contributions
IRET and MC performed research. EGC and JC contributed essential reagents
and analytical tools. IRET analyzed data. FP, OSG and MGM designed
research. IRET, FP, MGM and OSG wrote the paper. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 December 2010 Accepted: 7 June 2011
Published: 7 June 2011
Taravini et al. Molecular Neurodegeneration 2011, 6:40
http://www.molecularneurodegeneration.com/content/6/1/40
Page 11 of 12References
1. Fahn S: Description of Parkinson’s disease as a clinical syndrome. Ann N
Y Acad Sci 2003, 991:1-14.
2. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review
update: pharmacological and surgical treatments of Parkinson’s disease:
2001 to 2004. Mov Disord 2005, 20:523-539.
3. Isacson O, Bjorklund LM, Schumacher JM: Toward full restoration of
synaptic and terminal function of the dopaminergic system in
Parkinson’s disease by stem cells. Ann Neurol 2003, 53(Suppl 3):135-146.
4. Peterson AL, Nutt JG: Treatment of Parkinson’s disease with trophic
factors. Neurotherapeutics 2008, 5:270-280.
5. Rauvala H: An 18-kd heparin-binding protein of developing brain that is
distinct from fibroblast growth factors. EMBO J 1989, 8:2933-2941.
6. Rauvala H, Peng HB: HB-GAM (heparin-binding growth-associated
molecule) and heparin-type glycans in the development and plasticity
of neuron-target contacts. Prog Neurobiol 1997, 52:127-144.
7. Hida H, Jung CG, Wu CZ, Kim HJ, Kodama Y, Masuda T, Nishino H:
Pleiotrophin exhibits a trophic effect on survival of dopaminergic
neurons in vitro. Eur J Neurosci 2003, 17:2127-2134.
8. Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-
Vozari R, Murer MG, Ruberg M, Gershanik O: Differential gene expression
induced by chronic levodopa treatment in the striatum of rats with
lesions of the nigrostriatal system. J Neurochem 2004, 90:1348-1358.
9. Marchionini DM, Lehrmann E, Chu Y, He B, Sortwell CE, Becker KG,
Freed WJ, Kordower JH, Collier TJ: Role of heparin binding growth factors
in nigrostriatal dopamine system development and Parkinson’s disease.
Brain Res 2007, 1147:77-88.
10. Mourlevat S, Debeir T, Ferrario JE, Delbe J, Caruelle D, Lejeune O,
Depienne C, Courty J, Raisman-Vozari R, Ruberg M: Pleiotrophin mediates
the neurotrophic effect of cyclic AMP on dopaminergic neurons:
analysis of suppression-subtracted cDNA libraries and confirmation in
vitro. Exp Neurol 2005, 194:243-254.
11. Jung CG, Hida H, Nakahira K, Ikenaka K, Kim HJ, Nishino H: Pleiotrophin
mRNA is highly expressed in neural stem (progenitor) cells of mouse
ventral mesencephalon and the product promotes production of
dopaminergic neurons from embryonic stem cell-derived nestin-positive
cells. FASEB J 2004, 18:1237-1239.
12. Ferrario JE, Rojas-Mayorquín AE, Saldaña-Ortega M, Salum C, Gomes MZ,
Hunot S, Raisman-Vozari R: Pleiotrophin receptor RPTP-zeta/beta
expression is up-regulated by L-DOPA in striatal medium spiny neurons
of parkinsonian rats. J Neurochem 2008, 107:443-452.
13. Raulo E, Chernousov MA, Carey DJ, Nolo R, Rauvala H: Isolation of a
neuronal cell surface receptor of heparin binding growth-associated
molecule (HB-GAM). Identification as N-syndecan (syndecan-3). J Biol
Chem 1994, 269:12999-13004.
14. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F: Chronic
expression of low levels of tumor necrosis factor-alpha in the substantia
nigra elicits progressive neurodegeneration, delayed motor symptoms
and microglia/macrophage activation. Neurobiol Dis 2010, 37:630-640.
15. Ferrari CC, Pott Godoy MC, Tarelli R, Chertoff M, Depino AM, Pitossi FJ:
Progressive neurodegeneration and motor disabilities induced by
chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis 2006,
24:183-193.
16. Ferrari CC, Depino AM, Prada F, Muraro N, Campbell S, Podhajcer O,
Perry VH, Anthony DC, Pitossi FJ: Reversible demyelination, blood-brain
barrier breakdown, and pronounced neutrophil recruitment induced by
chronic IL-1 expression in the brain. Am J Pathol 2004, 165:1827-1837.
17. Ladeby R, Wirenfeldt M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L,
Dalmau I, Finsen B: Microglial cell population dynamics in the injured
adult central nervous system. Brain Res Brain Res Rev 2005, 48:196-206.
18. Perry VH, Hume DA, Gordon S: Immunohistochemical localization of
macrophages and microglia in the adult and developing mouse brain.
Neuroscience 1985, 15:313-326.
19. Sauer H, Oertel WH: Progressive degeneration of nigrostriatal dopamine
neurons following intrastriatal terminal lesions with 6-hydroxydopamine:
a combined retrograde tracing and immunocytochemical study in the
rat. Neuroscience 1994, 59:401-415.
20. Hida H, Masuda T, Sato T, Kim TS, Misumi S, Nishino H: Pleiotrophin
promotes functional recovery after neural transplantation in rats.
Neuroreport 2007, 18:179-183.
21. Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ: Cellular
distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in
developing and adult rat tissues. Anat Embryol (Berl) 1992, 186:387-406.
22. Wanaka A, Carroll SL, Milbrandt J: Developmentally regulated expression
of pleiotrophin, a novel heparin binding growth factor, in the nervous
system of the rat. Brain Res Dev Brain Res 1993, 72:133-144.
23. Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L,
Freed WJ: A novel combination of factors, termed SPIE, which promotes
dopaminergic neuron differentiation from human embryonic stem cells.
PLoS One 2009, 4:e6606.
24. Gramage E, Alguacil LF, Herradon G: Pleiotrophin prevents cocaine-
induced toxicity in vitro. Eur J Pharmacol 2008, 595:35-38.
25. Milev P, Chiba A, Häring M, Rauvala H, Schachner M, Ranscht B, Margolis RK,
Margolis RU: High affinity binding and overlapping localization of
neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with
tenascin-R, amphoterin, and the heparin-binding growth-associated
molecule. J Biol Chem 1998, 273:6998-7005.
26. Ramaswamy S, Kordower JH: Are growth factors the answer? Parkinsonism
Relat Disord 2009, 15(Suppl 3):176-180.
27. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H,
Saarma M, Männistö PT: Heparin-binding determinants of GDNF reduce
its tissue distribution but are beneficial for the protection of nigral
dopaminergic neurons. Exp Neurol 2009, 219:499-506.
28. Björklund A, Rosenblad C, Winkler C, Kirik D: Studies on neuroprotective
and regenerative effects of GDNF in a partial lesion model of
Parkinson’s disease. Neurobiol Dis 1997, 4:186-200.
29. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L:
Protection and repair of the nigrostriatal dopaminergic system by GDNF
in vivo. Nature 1995, 373:335-339.
30. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J,
Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD,
Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P:
Neurodegeneration prevented by lentiviral vector delivery of GDNF in
primate models of Parkinson’s disease. Science 2000, 290:767-773.
31. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C,
Mandel RJ, Annett L, Kirik D: Continuous low-level glial cell line-derived
neurotrophic factor delivery using recombinant adeno-associated viral
vectors provides neuroprotection and induces behavioral recovery in a
primate model of Parkinson’s disease. J Neurosci 2005, 25:769-777.
32. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ,
Mufson EJ, Penn R, Goetz CG, Comella CD: Clinicopathological findings
following intraventricular glial-derived neurotrophic factor treatment in
a patient with Parkinson’s disease. Ann Neurol 1999, 46:419-424.
33. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr,
Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF, ICV GDNF Study
Group: Implanted intracerebroventricular. Glial cell line-derived
neurotrophic factor: Randomized, double-blind trial of glial cell line-
derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
34. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS:
Intraputamenal infusion of glial cell line-derived neurotrophic factor in
PD: a two-year outcome study. Ann Neurol 2005, 57:298-302.
35. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM,
Milbrandt J, Deuel TF: Cloning and expression of a developmentally
regulated protein that induces mitogenic and neurite outgrowth
activity. Science 1990, 250:1690-1694.
36. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Academic
Press, San Diego; 1986.
37. Taravini IR, Ferrario JE, Delbe J, Ginestet L, Debeir T, Courty J, Murer MG,
Gershanik OS, Raisman-Vozari R: Immunodetection of heparin-binding
growth associated molecule (pleiotrophin) in striatal interneurons. Brain
Res 2005, 1066:196-200.
38. Festing MF: Guidelines for the design and statistical analysis of
experiments in papers submitted to ATLA (Alternatives to laboratory
animals). Altern Lab Anim 2001, 29:427-446.
doi:10.1186/1750-1326-6-40
Cite this article as: Taravini et al.: Pleiotrophin over-expression provides
trophic support to dopaminergic neurons in parkinsonian rats. Molecular
Neurodegeneration 2011 6:40.
Taravini et al. Molecular Neurodegeneration 2011, 6:40
http://www.molecularneurodegeneration.com/content/6/1/40
Page 12 of 12